Plan B Pharmacy Access Sales Growth Offers Silver Lining To FDA Delay – Barr
This article was originally published in The Tan Sheet
Executive Summary
Barr is testing a drugstore point-of-purchase program that directs consumers to ask their pharmacists about Plan B in states with pharmacy access to the emergency contraceptive
You may also be interested in...
Plan B: The Road Ahead
With at least 44,000 Plan B comments still under review at FDA, it is unclear when the agency will take its next step toward a decision on the proposed switch. In the meantime, those seeking OTC sale of EC are not keeping quiet on the issue. With lawsuits pending and pharmacy access to the drug increasing among individual states, there is plenty in store for Plan B in the coming year..
Plan B: The Road Ahead
With at least 44,000 Plan B comments still under review at FDA, it is unclear when the agency will take its next step toward a decision on the proposed switch. In the meantime, those seeking OTC sale of EC are not keeping quiet on the issue. With lawsuits pending and pharmacy access to the drug increasing among individual states, there is plenty in store for Plan B in the coming year..
Plan B: The Road Ahead
With at least 44,000 Plan B comments still under review at FDA, it is unclear when the agency will take its next step toward a decision on the proposed switch. In the meantime, those seeking OTC sale of EC are not keeping quiet on the issue. With lawsuits pending and pharmacy access to the drug increasing among individual states, there is plenty in store for Plan B in the coming year..